USA
Add to My Companies | Give a Referral for this Company | Print this ProfileThe latest news, announcements and press releases from Repertoire Immune Medicines.
CAMBRIDGE, Mass. – January 29, 2026 – Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced today that it has entered a strategic collaboration with Eli Lilly and Company (“Lilly”) to develop tolerizing therapies for multiple autoimmune diseases. The collaboration aims to develop treatments that restore immune homeostasis and provide patients with durable remission of their disease without the generalized immune suppression that is common with currently available therapies.
CAMBRIDGE, Mass. – April 23, 2025 – Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell-targeted immune medicines, today announced that it has entered into a collaboration and license agreement with Genentech, a member of the Roche Group, to discover and develop innovative T cell-targeted immune medicines to treat an autoimmune disease. Repertoire will deploy its DECODE™ platform, which uniquely maps the immune synapse, to discover novel therapeutic targets.
Collaboration combines Repertoire’s industry leading DECODE™ platform that uniquely maps the immune synapse to develop T cell targeted immune medicines with Bristol Myers Squibb’s world-leading expertise in developing and commercializing innovative immune medicines
Repertoire will receive an upfront payment of $65 million and is eligible to receive up to $1.8 billion in milestone and other payments and tiered royalties
This is the News section of the company profile page for Repertoire Immune Medicines on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
